Association of microRNA-33a Molecular Signature with Non-Small Cell Lung Cancer Diagnosis and Prognosis after Chemotherapy

Objective This study aims to explore the expression pattern and prognostic significance of miR-33a in non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy. Methods MiR-33aexpression in NSCLC was analyzed in silico using the GEO database and was subsequently confirmed by quantitative RT-PCR in 147 NSCLC biopsies. Among these, 32 of these biopsies were paired with adjacent non-neoplastic tissues. The survival analysis of NSCLC by Kaplan-Meier estimates was stratified based on miR-33a expression. In addition, multivariate survival analysis in corresponding groups of NSCLC patients was conducted by Cox proportional hazards regression model. Results The in silico analysis of miR-33a expression in NSCLC resulted to its down-regulation in different tumor types. The expression level of miR-33a was lower in each grade of NSCLC tumor biopsies than in normal lung tissues. Univariate and multivariate survival analysis further established that low miR-33a expression was an important risk factor for overall survival and disease free survival in NSCLC patients. Conclusion Our study implied that miR-33a expression levels may have an essential role in NSCLC progression, and could act as a specific and sensitive biomarker for NSCLC patients who have undergone adjuvant chemotherapy.

• Publication year

  2017

• Venue

  PLoS ONE

• Publication date

  2017-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1371/journal.pone.0170431PMID 28141816PMCID 5283662
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

  2016cited by this paper
• Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology.

  2016cited by this paper
• miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α

  2015cited by this paper
• Increased Expression of TGFβR2 Is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients Treated with Chemotherapy

  2015cited by this paper
• MircoRNA-33a inhibits epithelial-to-mesenchymal transition and metastasis and could be a prognostic marker in non-small cell lung cancer

  2015cited by this paper
• Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline.

  2015cited by this paper
• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• MiR-33a suppresses breast cancer cell proliferation and metastasis by targeting ADAM9 and ROS1

  2015cited by this paper
• miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST

  2014cited by this paper
• microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.

  2014cited by this paper
• miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways.

  2014cited by this paper
• Database resources of the National Center for Biotechnology Information

  2014cited by this paper
• Momordica Charantia lectin exhibits antitumor activity towards hepatocellular carcinoma

  2014cited by this paper
• Non-small cell lung cancer, version 1.2015.

  2014cited by this paper
• ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

  2013cited by this paper
• Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

  2013cited by this paper
• The long and short of microRNA.

  2013cited by this paper
• Management of non-small-cell lung cancer: recent developments.

  2013cited by this paper
• NCBI GEO: archive for functional genomics data sets—update

  2012cited by this paper
• Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers

  2012cited by this paper
• MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14)

  2011cited by this paper
• A Perspective on Cancer Cell Metastasis

  2011cited by this paper
• CA : A Cancer Journal for Clinicians

  2011cited by this paper
• MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.

  2011cited by this paper
• A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis.

  2011cited by this paper
• Identification of new aberrantly expressed miRNAs in intestinal-type gastric cancer and its clinical significance.

  2011cited by this paper
• Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer.

  2010cited by this paper
• MicroRNA control of signal transduction

  2010cited by this paper
• A MicroRNA targeting dicer for metastasis control.

  2010cited by this paper
• A Five-Gene and Corresponding Protein Signature for Stage-I Lung Adenocarcinoma Prognosis

  2010cited by this paper
• The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

  2010cited by this paper
• Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases

  2008cited by this paper
• A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer

  2008cited by this paper
• hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer

  2008cited by this paper
• Lung cancer.

  2008cited by this paper
• MicroRNA signature predicts survival and relapse in lung cancer.

  2008cited by this paper
• American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

  2007cited by this paper
• A five-gene signature and clinical outcome in non-small-cell lung cancer.

  2007cited by this paper
• American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.

  2007cited by this paper
• Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

  2006cited by this paper
• MicroRNAs: small RNAs with a big role in gene regulation

  2004cited by this paper
• Database resources of the National Center for Biotechnology Information: update

  2004cited by this paper
• A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

  2004cited by this paper
• Intensified Cloning Efforts Have Revealed Numer

  2004cited by this paper
• ' s report Title : Btbd 7 Contributes to reduced E-cadherin expression and Predicts Poor Prognosis in Non-small Cell Lung Cancer Version : 1

  year unknowncited by this paper

• Combination of hsa.let.7c and hsa.mir.3622a as Potential miRNA in Uterine Cancer Diagnosis: RNA Seq and Deep Learning

  2026cites this paper
• DeMoS: dense module based gene signature detection through quasi-clique: an application to cervical cancer prognosis

  2024cites this paper
• Abnormal Gene Expression Regulation Mechanism of Myeloid Cell Nuclear Differentiation Antigen in Lung Adenocarcinoma

  2022cites this paper
• Epi‐miRNAs: Modern mediators of methylation status in human cancers

  2022cites this paper
• Epigenetics and precision medicine in lung cancer

  2022cites this paper
• APE1 controls DICER1 expression in NSCLC through miR-33a and miR-130b

  2022cites this paper
• A Multi-Molecular Fusion to Detect Transcriptomic Signature in Tissue-Specific Cancer

  2022cites this paper
• Clinical Value and Potential Mechanism of miRNA-33a-5p in Lung Squamous Cell Carcinoma

  2021cites this paper
• Serotonin-induced miR-221/222 contribute to the activation of hepatic stellate cells

  2020cites this paper
• Identification of three miRNAs signature as a prognostic biomarker in breast cancer using bioinformatics analysis

  2020cites this paper
• miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer.

  2020cites this paper
• Overexpression of microRNA-124-5p sensitizes non-small cell lung cancer cells to treatment with 5-fluorouracil via AEG-1 regulation.

  2020cites this paper
• MicroRNAs Associated With Colon Cancer: New Potential Prognostic Markers and Targets for Therapy

  2020cites this paper
• Role of microRNA-33a in malignant cells

  2020influential citation
• Circulating miR-1246 Targeting UBE2C, TNNI3, TRAIP, UCHL1 Genes and Key Pathways as a Potential Biomarker for Lung Adenocarcinoma: Integrated Biological Network Analysis

  2020cites this paper
• DeMoS: Dense Module-based Gene Signature Detection through Quasi-Clique: An Application for Cervical Cancer Prognosis

  2020cites this paper
• MicroRNAs associated with lung squamous cell carcinoma: New prognostic biomarkers and therapeutic targets

  2019cites this paper
• RASSF1C regulates miR-33a and EMT marker gene expression in lung cancer cells

  2019cites this paper
• A five-miRNA signature predicts survival in gastric cancer using bioinformatics analysis.

  2019cites this paper
• microRNA-33a prevents epithelial-mesenchymal transition, invasion and metastasis of gastric cancer cells through the Snail/Slug pathway.

  2019cites this paper
• Hsa-mir-210 as a novel signature predicts survival in lung squamous cell carcinoma using bioinformatics analysis

  2019cites this paper
• Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-β signaling

  2019cites this paper
• Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma

  2018cites this paper
• A FOUR MIRNAS SIGNATURE AS A POTENTIAL BIOMARKER FOR PREDICTING SURVIVAL USING BIOINFORMATICS ANALYSIS IN BLADDER CANCER: MP58‐12

  2018cites this paper
• Prognostic implications of decreased microRNA-101-3p expression in patients with non-small cell lung cancer

  2018cites this paper
• MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis

  2018cites this paper
• Reduced hsa-miR-124-3p levels are associated with the poor survival of patients with hepatocellular carcinoma

  2018cites this paper
• miR-30 Family Reduction Maintains Self-Renewal and Promotes Tumorigenesis in NSCLC-Initiating Cells by Targeting Oncogene TM4SF1.

  2018cites this paper
• Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art

  2018cites this paper
• Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14.

  2018cites this paper
• MicroRNA expression in cervical cancer: Novel diagnostic and prognostic biomarkers

  2018cites this paper
• High expression of miR-493-5p positively correlates with clinical prognosis of non small cell lung cancer by targeting oncogene ITGB1

  2017cites this paper
• Identification of miR-124a as a novel diagnostic and prognostic biomarker in non-small cell lung cancer for chemotherapy

  2017cites this paper
• Upregulation of miR-181a suppresses the formation of glioblastoma stem cells by targeting the Notch2 oncogene and correlates with good prognosis in patients with glioblastoma multiforme.

  2017cites this paper
• A three miRNAs signature predicts survival in cervical cancer using bioinformatics analysis

  2017cites this paper